US 12,083,092 B2
Antiviral 1,3-di-oxo-indene compounds
Johan Neyts, Kessel-Lo (BE); Daniel Poon, Piedmont, CA (US); Keith Bruce Pfister, Emeryville, CA (US); Young-Sik Jung, Daejeon (KR); Soo Bong Han, Daejeon (KR); Yashwardhan R. Malpani, Daejeon (KR); Prashant Chakrasali, Daejeon (KR); Sang-Ho Lee, Daejeon (KR); Chong-Kyo Lee, Daejeon (KR); Chonsaeng Kim, Daejeon (KR); Jin Soo Shin, Daejeon (KR); and Hae Soo Kim, Daejeon (KR)
Assigned to Novartis AG, Basel (CH); Katholieke Universiteit Leuven, Leuven (BE); and Korea Research Institute of Chemical Technology, Daejeon (KR)
Filed by Novartis AG, Basel (CH); Katholieke Universiteit Leuven, Leuven (BE); and Korea Research Institute of Chemical Technology, Daejeon (KR)
Filed on Apr. 20, 2021, as Appl. No. 17/235,140.
Claims priority of provisional application 63/012,770, filed on Apr. 20, 2020.
Prior Publication US 2021/0322362 A1, Oct. 21, 2021
Int. Cl. A61K 31/343 (2006.01); A61P 31/14 (2006.01); C07D 307/93 (2006.01)
CPC A61K 31/343 (2013.01) [A61P 31/14 (2018.01); C07D 307/93 (2013.01)] 31 Claims
 
1. A compound of Formula [I], or a pharmaceutically acceptable salt thereof:

OG Complex Work Unit Chemistry
wherein,
one of G1 and G2 is selected from linear or branched C1-C5 alkyloxy; linear or branched C1-C5 haloalkyl; linear or branched C1-C5 haloalkyloxy; halo and 3-7 membered cycloalkyl; and the other of G1 and G2 is H; and R1 is selected from H and linear or branched C1-C5 alkyl.
 
19. A pharmaceutical composition comprising the compound of claim 1, a pharmaceutically acceptable salt thereof or optical isomer thereof and a pharmaceutically acceptable diluent or excipient.